Psychedelics Weekly – Research Explained: Ket...

Jen Davenport joins Psychedelics Today to interview co-founder Joe Moore about the growth of Psychedelics Today, the broader psychedelic ecosystem, and how professionals are beginning to engage with psychedelic ideas. Davenport is the founder of Iron Thread Partners and a graduat ...  Show more

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psyched ...  Show more

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Show more

We’re in the midst of a psychedelic renaissance, where this once demonized class of drugs is now front and center receiving attention among entrepreneurs, investors, clinical trials and even patients. In this special conversation, TED Health’s Dr. Shoshana Ungerleider speaks with ...  Show more

Dr. Paul Liknaitsky is the head of clinical psychedelic research at Monash University Australia. He is conducting world-first clinical trials into the use of magic mushrooms and ecstasy to treat depression, anxiety, and PTSD. This is his second time on this podcast to chat about ...  Show more